Galderma Group
CHF 160.55Change from previous close: −0.16%Absolute change: −CHF 0.25
At a glance
- Revenue growth
- +18.04%
- 2025 vs 2024
- Net income growth
- +165.37%
- 2025 vs 2024
- Net margin
- 11.7%
- 2024: 5.2%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 1,185 | 488 | 165 | 111 | 196 |
| Depreciation and amortization | 286 | 249 | 236 | 251 | 239 |
| Capital expenditure | -113 | -128 | -121 | -102 | -49.9 |
| Investing cash flow | -154 | -326 | -174 | -66.5 | -523 |
| Financing cash flow | -728 | -58.0 | 142 | -79.4 | 307 |
| Dividends paid | -41.0 | — | — | — | — |
| Share repurchases | -363 | -15.0 | 0.0 | — | — |
| Debt issued | 1,408 | 3,601 | 856 | 400 | — |
| Debt repaid | -1,701 | -5,777 | -1,725 | -472 | — |
| Effect of exchange rates | 20.0 | -14.0 | 0.0 | -24.9 | -16.5 |
| Net change in cash | 323 | 89.0 | 134 | -59.5 | -37.1 |
| Free cash flow | 1,072 | 360 | 44.0 | 9.7 | 146 |
| Levered free cash flow | 905 | 131 | 136 | 196 | — |